How far away from having an effective treatment option for progressive multiple sclerosis are we?-Reference-Cited by-同舟云学术

How far away from having an effective treatment option for progressive multiple sclerosis are we?

Published:2017-05-16 Issue:10 Volume:18 Page:953-955
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Sartori Arianna¹^ORCID,Fantini Jacopo¹^ORCID,Manganotti Paolo¹^ORCID

Affiliation:

1. Department of Medical, Surgical, and Health Sciences, University of Trieste, Azienda Sanitaria Universitaria Integrata di Trieste, Neurology Unit – Cattinara Hospital, Trieste, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1326909

Reference21 articles.

1. Pathological mechanisms in progressive multiple sclerosis

2. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

3. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

4. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

5. Mitoxantrone for multiple sclerosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: intermediate results of 3 years research;Russian neurological journal;2023-01-10

2. Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups;Frontiers in Immunology;2021-03-10

3. Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients;Frontiers in Neuroscience;2019-10-04

4. Progress and prospects of metabolic therapy in multiple sclerosis;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2019

5. Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy;Immunological Investigations;2017-11-28